TP53 and neoplasm: Assuming that resistance of advanced forms of CRC to chemotherapy is often associated with the presence of TP53 mutations in the tumor, the AN-238 analogue, consisting of 2-pyrrolinodoxorubicin (AN-201) linked to octapeptide SRIF carrier RC-12, was tested in CRC cell lines with wt p53 (HCT-116, LoVo cells), and p53 mutation (HCT-15, HT-29 cells).